- August 11, 2021Annovis Bio Completes Dosing of Parkinson’s Disease Patients with ANVS401 in Phase 2a Clinical Trial
- July 30, 2021Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease
- July 28, 2021Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference
- October 01, 2019Axonal Transport and Neurological Disease
- May 21, 2019How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
- April 30, 2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’s
Back to Top